ENDRA Life Sciences (NASDAQ:NDRA) Stock Rating Upgraded by Zacks Investment Research

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Separately, HC Wainwright cut their price target on ENDRA Life Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, April 7th.

ENDRA Life Sciences stock opened at $0.23 on Thursday. The business has a 50-day simple moving average of $0.31 and a two-hundred day simple moving average of $0.61. The company has a market cap of $10.14 million, a P/E ratio of -0.82 and a beta of 1.40. ENDRA Life Sciences has a 52-week low of $0.18 and a 52-week high of $2.44.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last released its quarterly earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter. During the same quarter last year, the company posted ($0.10) earnings per share. On average, equities research analysts forecast that ENDRA Life Sciences will post -0.26 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in shares of ENDRA Life Sciences during the 3rd quarter valued at approximately $26,000. Raymond James & Associates bought a new position in shares of ENDRA Life Sciences during the 4th quarter valued at approximately $49,000. Virtu Financial LLC bought a new position in shares of ENDRA Life Sciences during the 4th quarter valued at approximately $50,000. Royal Bank of Canada grew its stake in shares of ENDRA Life Sciences by 65.3% during the 2nd quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock valued at $55,000 after acquiring an additional 10,000 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of ENDRA Life Sciences by 60.9% during the 1st quarter. Renaissance Technologies LLC now owns 349,300 shares of the company’s stock valued at $136,000 after acquiring an additional 132,220 shares during the period. Institutional investors own 10.03% of the company’s stock.

ENDRA Life Sciences Company Profile (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

Read More

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.